OneAscent Financial Services LLC Has $243,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

OneAscent Financial Services LLC reduced its holdings in Amgen Inc. (NASDAQ:AMGN) by 14.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 753 shares of the medical research company’s stock after selling 126 shares during the period. OneAscent Financial Services LLC’s holdings in Amgen were worth $243,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of AMGN. Capital Performance Advisors LLP bought a new position in Amgen during the third quarter worth $25,000. Strategic Financial Concepts LLC bought a new position in shares of Amgen during the 2nd quarter worth about $26,000. Hershey Financial Advisers LLC acquired a new position in shares of Amgen during the second quarter valued at about $30,000. nVerses Capital LLC bought a new stake in shares of Amgen in the second quarter valued at about $31,000. Finally, Bbjs Financial Advisors LLC acquired a new stake in Amgen during the second quarter worth about $33,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

AMGN opened at $279.95 on Wednesday. The company has a fifty day moving average price of $318.92 and a two-hundred day moving average price of $318.43. The firm has a market capitalization of $150.48 billion, a PE ratio of 35.85, a P/E/G ratio of 2.53 and a beta of 0.60. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same period in the previous year, the firm earned $4.96 earnings per share. The firm’s quarterly revenue was up 23.2% compared to the same quarter last year. As a group, analysts anticipate that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 3.21%. The ex-dividend date is Monday, November 18th. Amgen’s payout ratio is 115.24%.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of research reports. Barclays raised their price objective on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $305.00 price target (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, TD Cowen upped their target price on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and a consensus price target of $333.57.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.